18th MEET THE PROFESSOR
Advanced International Breast Cancer Course 2022
(AIBCC 2022)
Padua and online
Presentation
Aims
Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.
New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, tio allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
The 18th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.
Addressed to
Scientific Program
Thursday, November 3rd
10:00 | Introduction to the Conference Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat |
SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION
Chairpersons: Hesham Ahmed Gaballah Elghazaly, Aleix Prat
10:30 | Biological heterogeneity and clinical outcomes in HR+/HER2-negative disease Maria Vittoria Dieci |
11:00 | PDL1, TMB, TROP2, immune infiltration and genomic classifiers in TNBC Giampaolo Bianchini |
11:30 | Is HER2-low breast cancer a real entity? Scoring issues and biological heterogeneity Giuseppe Viale |
12:00 | HER2+ early breast cancer: potential role of genomic classifiers Aleix Prat |
12:30 | Q&A |
13:00 | Lunch |
SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS
Mastectomy, breast reconstruction and radiation Therapy
Chairpersons: Jaceck Jassem, Philip Poortmans
14:00 | When is breast-conserving therapy really not avoidable Oreste Gentilini |
14:30 | Breast reconstruction: when and how? Vincenzo Vindigni |
15:00 | Radiation therapy after breast reconstruction Orit Kaidar-Person |
15:30 | Q&A |
Multidisciplinary Tumor Board 1 – Locoregional treatment Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Fedro Peccatori |
|
16:00 | Clinical case 1. Second breast conserving therapy Tania Saibene |
16:15 | Clinical case 2. Patient with lymph node seen on planning CT-scan: what now? (RT) Silvia Michieletto |
16:30 | Clinical case 3: BOOP: after or due to radiation therapy Luca Visani |
16:45 | Concluding comments Eleftherios Mamounas, Fedro Peccatori |
17:00 | Adjourn |
17:45 | Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2022 |
18:00 | Lecture of the Awardee |
18:30 | Cocktail |
19:00 | Adjourn |
The Ceremony and the cocktail will take place in
Palazzo Bo, Via VIII Febbraio 2, Padua
Friday, November 4th
SESSION III – EARLY BREAST CANCER. FINE TUNING FROM DE-ESCALATION TO ESCALATION
Chairpersons: Pierfranco Conte, Miguel Martin.
09:00 | Tailoring neoadjuvant/adjuvant treatment for triple negative breast cancer Sibylle Loibl |
09:30 | Risk adapted treatment of early HR+/HER2- breast cancer: from modulation of endocrine treatment to novel agents Stephen Johnston |
10:00 | Is there a role for anthracyclines in contemporary treatment of early breast cancer? Valentina Guarneri |
10:30 | Q&A |
11:00 | Coffee Break |
Multidisciplinary Tumor Board 2 – Early breast cancer Panelists: Bettina Borisch, Pierfranco Conte, Valentina Guarneri, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Miguel Martin, Fedro Peccatori |
|
11:30 | Clinical case 1. Node positive, premenopausal patient: role of genomic classifiers Cristina Falci |
11:45 | Clinical case 2. HR+HER2+ patient with residual disease after neoadjuvant therapy Federica Miglietta |
12:00 | Clinical case 3. Adjuvant treatment in rare histologies Grazia Vernaci |
12:15 | Concluding comments Jaceck Jassem, Miguel Martin |
12:30 | Lunch |
SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS
Chairpersons: Alessandra Gennari, Bettina Borisch.
13:30 | HER2+ advanced breast cancer: new treatment algorithms Sandra Swain |
14:00 | TN advanced breast cancer: biology-driven treatment algorithms Hope Rugo |
14:30 | HR+ advanced breast cancer: what after CDK4/6? Giuseppe Curigliano |
15:00 | Q&A |
Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer Panelists: Bettina Borisch, Pierfranco Conte, Giuseppe Curigliano, Hesham Ahmed Gaballah Elghazaly, Hope Rugo, Sandra Swain |
|
15:30 | Clinical case 1. Brain metastases Gaia Griguolo |
15:45 | Clinical case 2. Possibility of discontinuing treatment in very long term responders Carlo Alberto Giorgi |
16:00 | Clinical case 3. Locoregional treatment for oligometastatic disease or role of NGS in ABC Michele Bottosso |
16:15 | Concluding comments Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly |
16:30 | Take home messages and adjourn |
CME (In-Class & Online)
Based on the applicable regulation, Accademia Nazionale di Medicina (CME provider n. 31) will assign to the activity (ECM 31-355554): 8,4 CME points.
Training objective: professional and technical content (knowledge and skills) specific to each profession, specialization and highly specialized activity. Rare disease.
The credit certification for the course is subject to the fulfillment of all following conditions:
- Professions/specializations should correspond to those accredited for CME
- Attendance no lower than 90% of the meeting duration
- Completion of the meeting evaluation online form
- Completion of the final test (at least 75% of correct answers). 1 attempt admitted.
- Ownership of an Italian Fiscal Code (Codice Fiscale).
The test and the meeting evaluation form must be completed within 3 days from the end of the event.
Award & Fellowship
Faculty
Honorary President
Directors
Scientific Commitee
Bettina Borisch
Geneve (CH)
Maria Vittoria Dieci
Padova (I)
Hesham Ahmed Gaballah Elghazaly
Cairo (EG)
Jacek Jassem
Gdansk (PL)
Stephen Johnston
London (UK)
Sibylle Loibl
Frankfurt (D)
Eleuterios Mamounas
Orlando (USA)
Miguel Martin
Madrid (E)
Fedro Alessandro Peccatori
Milano (I)
Sandra M. Swain
Washington (USA)
Speakers
Giampaolo Bianchini
Milano (I)
Michele Bottosso
Padova (I)
Giuseppe Curigliano
Milano (I)
Maria Vittoria Dieci
Padova (I)
Cristina Falci
Padova (I)
Alessandra Gennari
Novara(I)
Valentina Guarneri
Padova (I)
Oreste Davide Gentilini
Milano (I)
Carlo Alberto Giorgi
Padova (I)
Gaia Griguolo
Padova (I)
Orit Kaidar-Person
Ramat Gan (IL)
Stephen Johnston
London (UK)
Sibylle Loibl
Frankfurt (D)
Silvia Michieletto
Padova (I)
Federica Miglietta
Padova (I)
Aleix Prat
Barcellona (E)
Hope Rugo
San Francisco (USA)
Tania Saibene
Padova (I)
Sandra Swain M.
Washington (USA)
Grazia Vernaci
Padova (I)
Giuseppe Viale
Milano (I)
Vincenzo Vindigni
Padova (I)
Luca Visani
Firenze (I)
Under the Patronage
Supported by unrestricted educational grants from
GOLD SPONSOR

SILVER SPONSOR



BRONZE SPONSOR

